Skip to content
March 14, 2024

Equity.Guru

Investment information for the new generation

Search

Medical marijuana

Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, has announced that is has signed a Definitive Agreement with DanCann Pharma for the exclusive distribution of Reduvo™…
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds…
CANN focuses on extraction and the creation of derivative products for recreational and medical consumers….
Investing is a particularly fluid art. This fluidity shows itself in the selection of an appropriate intrinsic value. And it is always best to go back and recheck your…
CannaCure’s goal is “to transform the global marijuana landscape through innovative growth strategies and strategic partnerships with manufacturers of cannabis products.”…
Sharples believes that Purefarma, Pura Vida, new contract manufacturing agreements, expansion of Canadian territories, the edibles product launch and the acquisition of Opticann expanding CANN’s U.S. presence will accelerate…
Heritage is positioning itself to radically expand its sales territory….
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”….
Medical Marijuana (MJNA.OTC) announced today that their investment company AXIM Biotechnologies (AXIM.OTC) has signed a binding term sheet to acquire oncology research and development company Sapphire Biotech. Sapphire engages…
A scrappy pioneer industry like cannabis attracts CEOs with diverse backgrounds. Before becoming a weed titan, Bruce Linton, the CEO of Canopy Growth (WEED.T) was an IT executive. Adam…